Harwood Feffer LLP Announces it Has Amended Its Class Action Complaint Against Genzyme Corporation (GENZ)
27 1월 2011 - 3:45AM
Harwood Feffer LLP today announced that on January 18, 2011 the
firm amended its class action complaint against Genzyme Corporation
("Genzyme Corporation" or the "Company") (Nasdaq:GENZ) and its
Board of Directors to include claims of violations under Section 14
and Section 20 of the Securities Exchange Act of 1934.
The consolidated action, entitled In Re Genzyme Corporation
Shareholder Litigation, Master Docket No. 1:10-CV-11356, is pending
in the United States District Court for the District of
Massachusetts and names as defendants, Genzyme, the Company's
Chairman and CEO, Henri A. Termeer, and other members of the
Company's Board of Directors. A copy of the complaint can be
obtained from the Court.
The complaint charges that the defendants breached their
fiduciary duties to the Company's shareholders and violated the
Securities Exchange Act of 1934. More specifically, the complaint
alleges that defendants failed to disclose certain material facts
in connection with the proposal to acquire the Company by
Sanofi-Aventis, publicly announced on August 29, 2010, and that the
14D-9 defendants filed with the SEC on October 7, 2010 and
disseminated to Genzyme shareholders thereafter, wherein the Board
recommended shareholders not tender their shares, contained
materially misleading information. The complaint also includes
claims for breach of fiduciary duty. It is brought on behalf of a
class of all Genzyme shareholders except for the named defendants
and persons or entities related to or affiliated with the
defendants.
If you own Genzyme shares, you may request that the Court
appoint you as lead plaintiff by April 18, 2011. A lead plaintiff
is a representative party that acts on behalf of other class
members in directing the litigation. In order to be appointed lead
plaintiff, the Court must determine that the class member's claim
is typical of the claims of other class members, and that the class
member will adequately represent the class. Under certain
circumstances, one or more class members may together serve as
"lead plaintiff." Your ability to share in any recovery is not,
however, affected by the decision whether or not to serve as a lead
plaintiff. You may retain Harwood Feffer, or other counsel of your
choice, to serve as your counsel in this action.
Harwood Feffer has taken a leading role in many important
actions on behalf of defrauded shareholders. The Harwood Feffer
website (www.hfesq.com) has more information about the firm and
detailed information regarding this matter. If you wish to discuss
this action with us, or have any questions concerning this notice
or your rights and interests with regard to the case, please
contact the firm.
The Harwood Feffer LLP logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=454
CONTACT: Jeffrey M. Norton, Esq.
Harwood Feffer LLP
488 Madison Ave., 8th Floor
New York, New York 10022
Toll Free Telephone: (877) 935-7400
jnorton@hfesq.com
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025